Table 2.

Univariate analyses of progression-free and overall survival in 95 patients from the EURTAC trial included in the present study

PFSOverall survival
VariableHR (95% CI)PHR (95% CI)P
Gender
 Female1.001.00
 Male1.05 (0.63–1.76)0.84870.955 (0.54–1.69)0.8742
Treatment
 Chemotherapy1.001.00
 Erlotinib0.32 (0.19–0.53)< 0.00010.96 (0.59–1.57)0.8651
Smoking history
 Current smoker1.001.00
 Never smoked0.68 (0.29–1.60)0.37740.55 (0.23–1.29)0.1688
 Former smoker0.75 (0.30–1.90)0.54240.56 (0.22–1.46)0.2392
ECOG performance status
 1, 21.001.00
 00.71 (0.43–1.18)0.18340.70 (0.41–1.20)0.1939
Bone metastasis
 No1.001.00
 Yes1.45 (0.86–2.42)0.16150.89 (0.51–1.57)0.6915
Brain metastasis
 No1.001.00
 Yes2.02 (0.80–5.10)0.13471.11 (0.48–2.58)0.8102
Type of EGFR mutation
 del 191.001.00
 L858R1.05 (0.65–1.71)0.83301.41 (0.85–2.34)0.1805
T790M mutation
 Not detected1.001.00
 Detected1.36 (0.82–2.26)0.22790.998 (0.59–1.69)0.9941
TP53 mutations (n = 82)
 Not detected1.001.00
 Detected1.67 (0.94–2.97)0.07941.41 (0.78–2.53)0.2546
BIM expression (n = 83)
 Low/intermediate1.001.00
 High0.54 (0.31–0.93)0.02610.55 (0.31–0.97)0.0395

Abbreviation: ECOG, Eastern Cooperative Oncology Group.